AbbVie announces positive results from Viekira Pak study
Global biopharmaceutical company AbbVie (NYSE: ABBV) has announced positive results from a Phase IIIb trial evaluating Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets, dasabuvir tablets) in a diverse patient population with chronic hepatitis C virus (HCV) infection.
Results from the multicenter trial in the USA showed that 95% of patients in the TOPAZ-II study achieved a sustained virologic response (SVR) post-treatment. The data was presented this week at the Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
The trial examined the impact of SVR on the progression of liver diseases over the course of five years in a diverse patient population, including genotype 1a and 1b (GT1a and GT1b) HCV patients with or without cirrhosis and those who were treatment-naïve or pegylated interferon (pegIFN) /ribavirin (RBV) treatment-experienced.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze